What is the future of medtech in 2018?


medtech future leap jump inspiration risk

[Photo by Jordan McQueen on Unsplash]

Some of the largest medtech companies showed in 2017 that they are ready to grow through embrace of the new healthcare ecosystem.

Medical device companies are putting greater emphasis on value-based arguments for their products and services. They’re putting more attention to clinical and economic research and adopting digital products that incorporate machine learning and data integration.

Questions, though, still remain as we enter 2018. The editors at MDO asked several experts – many at the recent DeviceTalks West in Orange County, Calif. – to weigh in on what they believe will happen in the coming year. Some offered insight into FDA’s future, as well as the future of global regulatory bodies. Others focused on how healthcare policies and patent law trends will impact medical device businesses. And some looked at technology, most importantly, the convergence of digital technology and device technology – and shared the trends they expect to see in the coming year.

Read on to discover the experts’ thoughts about important trends facing the industry.


Managing editor Chris Newmarker contributed to this report.

NEW! Technology Track at DeviceTalks Boston

textadimage These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.

View Technology Track Featured Sessions

Register today to save. Use code TECHTRACK to save an additional 10%.

Pages: 1 2 3 4 5 6 7 8


  1. Alok Sharma says:

    In the year 2018, device industry must cohesively work more with Pharma companies to add value to the life of the patients. The disease and the disease patterns are changing & so the long term outcomes. Doctors / practitioners/ Companies & regulatory authorities must look at the side effects of post implantation of a device and prescribe medications so that long term outcomes of the patients are better with low side effects. Not all patients globally have an insurance Cover. Adipose tissue derived autologous Stem Cells treatment must get speedy approvals from regulatory authorities.

Speak Your Mind